Stock Market News
Scancell Holdings pens manufacturing agreement for cancer therapy candidate
Cancer treatment developer Scancell Holdings has signed a manufacturing agreement for its first moditope development candidate with The PolyPeptide Group, the company said on Tuesday.
The Modi-1 AMPLIVANT conjugate is intended to overcome the immune suppression induced by tumours through the stimulation of production of T cells, which seek out and kill cancer cells that would otherwise be hidden from the immune system.
Cliff Holloway, chief executive of Scancell Holdings, said: "Commencing GMP manufacture is an important step in the development of our first moditope product and is key to moving this novel therapy into the clinic in the first half of 2019."
Pre-clinical data has demonstrated that the conjugation of Modi-1 peptides to AMPLIVANT enhances immune responses against tumours by between ten and 100 fold.
The company plans to commence a phase 1 / 2 clinical trial of the product in the first half of 2019, measuring the effects on patients with triple negative breast cancer, ovarian cancer and sarcomas.
Jane Salik, chief executive of The PolyPeptide Group, said: "We are very pleased to have been selected by Scancell to manufacture Modi-1-AMPLIVANT® as this recognises our capabilities and reputation as a world leading GMP-compliant manufacturer of therapeutic peptides."
The Modi-1 AMPLIVANT conjugate has been developed through Scancell's exclusive worldwide licence to use ISA Pharmaceuticals' AMPLIVANT immunoptherapy technology, which the company acquired in February.
As of 1111 BST, Scancell Holdings' shares were up 5.45% at 14.50p.
The Modi-1 AMPLIVANT conjugate is intended to overcome the immune suppression induced by tumours through the stimulation of production of T cells, which seek out and kill cancer cells that would otherwise be hidden from the immune system.
Cliff Holloway, chief executive of Scancell Holdings, said: "Commencing GMP manufacture is an important step in the development of our first moditope product and is key to moving this novel therapy into the clinic in the first half of 2019."
Pre-clinical data has demonstrated that the conjugation of Modi-1 peptides to AMPLIVANT enhances immune responses against tumours by between ten and 100 fold.
The company plans to commence a phase 1 / 2 clinical trial of the product in the first half of 2019, measuring the effects on patients with triple negative breast cancer, ovarian cancer and sarcomas.
Jane Salik, chief executive of The PolyPeptide Group, said: "We are very pleased to have been selected by Scancell to manufacture Modi-1-AMPLIVANT® as this recognises our capabilities and reputation as a world leading GMP-compliant manufacturer of therapeutic peptides."
The Modi-1 AMPLIVANT conjugate has been developed through Scancell's exclusive worldwide licence to use ISA Pharmaceuticals' AMPLIVANT immunoptherapy technology, which the company acquired in February.
As of 1111 BST, Scancell Holdings' shares were up 5.45% at 14.50p.
Related share prices |
---|
Scancell Holdings (SCLP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price